CNSX:VP Vodis Pharmaceuticals (VP) Stock Price, News & Analysis Add Compare Share Share Stock Analysis Stock Analysis About Vodis Pharmaceuticals Stock (CNSX:VP) Get Vodis Pharmaceuticals alerts:Sign Up Key Stats Today's Range N/A50-Day Range N/A52-Week Range N/AVolume51,582 shsAverage Volume1,714 shsMarket CapitalizationN/AP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company Overview Vodis Pharmaceuticals Inc. operates as an application stage company for producing medical marijuana. It operates in Canada and the United States. The company is based in Delta, Canada. Read More Receive VP Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Vodis Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. VP Stock News HeadlinesVP debate 'spin room' scene: Talking points and unscripted momentsOctober 22, 2024 | usatoday.comVice President Harris in ‘Excellent Health,’ Medical Report StatesOctober 14, 2024 | msn.comHow options let you do more with less capitalWould you rather spend $5,000 buying 100 shares of a $50 stock, or control those same 100 shares for a fraction of the cost? That's the core advantage options offer traders at every level. The Beginner's Guide to Options breaks down leverage, income strategies, and real trade examples in plain English — including a little-known approach many traders use to reduce costs and improve profit potential. Download your free copy before this offer expires.October 2 at 1:00 AM | Base Camp Trading (Ad)Vance Confident, Walz Uneven in VP Debate Heavy on PolicyOctober 2, 2024 | wsj.comRead the full VP debate transcript from the Walz-Vance showdownOctober 2, 2024 | cbsnews.comAs Investigations Swirl, Another Adams Official ResignsSeptember 24, 2024 | nytimes.comTonix Pharmaceuticals Announces Appointment of Thomas Englese as Executive Vice President of Commercial OperationsSeptember 10, 2024 | markets.businessinsider.comKalVista Pharma Appoints Brian Piekos As New CFOSeptember 10, 2024 | markets.businessinsider.comSee More Headlines VP Stock Analysis - Frequently Asked Questions How do I buy shares of Vodis Pharmaceuticals? Shares of VP stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Vodis Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some other companies that Vodis Pharmaceuticals investors own include Ampliphi Biosciences (APHB), Apellis Pharmaceuticals (APLS), Athersys (ATHX), Iovance Biotherapeutics (IOVA), Arbutus Biopharma (ABUS) and Aurora Cannabis (ACBFF). Industry, Sector and Symbol Stock ExchangeCNSX SectorHealthcare Industry Biotechnology Sub-IndustryBiotechnology Current SymbolCNSX:VP CIKN/A Webvodis.ca Phone778-990-8985FaxN/AEmployeesN/AYear FoundedN/AProfitability EPS (Trailing Twelve Months)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity RatioN/A Current RatioN/A Quick RatioN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book ValueN/A Price / BookN/AMiscellaneous Outstanding SharesN/AFree FloatN/AMarket CapN/A OptionableNot Optionable BetaN/A The 10 Best High-Yield Dividend Stocks for 2026Discover the 10 Best High-Yield Dividend Stocks for 2026 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.Get This Free Report This page (CNSX:VP) was last updated on 10/2/2026 by MarketBeat.com Staff. From Our PartnersElon Warns "America Will Go Bankrupt". Trump's Plan Inside.National debt just crossed 40 trillion dollars, and Elon Musk says America is 1,000% going to go bankrupt with...American Hartford Gold | SponsoredMILLIONAIRE MASTERCLASS INVITE: AltucherJames Altucher says Elon Musk is preparing an unprecedented project set to surface on December 8th. Altuche...Paradigm Press | SponsoredTrump goes "all-in" on Grand Canyon energy breakthroughA drilling crew near the Grand Canyon uncovered a clean energy well producing nearly eight times the output of...Behind the Markets | SponsoredHow Elon’s Empire Ends (and how to profit)Marc Chaikin, the 60 year Wall Street veteran whose Chaikin Money Flow indicator sits on every Bloomberg termi...Chaikin Analytics | SponsoredTrump's New DollarPorter Stansberry says President Trump has signed an executive order initiating what he calls a full U.S. doll...Porter & Company | SponsoredMy next big call (under $1)Crypto traders have a name for this month... Uptober. Since 2013, Bitcoin has closed October higher in 10 of 1...Crypto 101 Media | SponsoredNew Chip takes minutes, not daysGeorge Gilder believes today's AI data centers could become tomorrow's typewriters - replaced by a single wafe...Eagle Publishing | SponsoredMajor Buy Alert Issued for October 31stKeith Kaplan has invested $17 million into his own AI research tools, building a platform now used by 180,000 ...TradeSmith | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Vodis Pharmaceuticals Inc Please log in to your account or sign up in order to add this asset to your watchlist. Share Vodis Pharmaceuticals With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.